Kornimate/medical-research-clean huggingface dataset:
feasibility study of fiducial markers in oesophageal cancer

Conditions: Esophageal Neoplasms

Summary: currently, patients of suitable fitness with non-metastatic esophageal cancer are treated with surgery, radiotherapy or chemoradiotherapy. if treated with radio or chemoradiotherapy, a computerised tomography (ct) scan is performed and is the dataset used for planning radiotherapy. information from the endoscopic ultrasound (eus), performed during routine staging, is used to help localize the tumor, as tumors of the esophagus are poorly visualised on ct. this information is subjective and dependant on the clinician performing the procedure. the tumor is described in relation to common anatomical landmarks. interpretion of this information can lead to over-compensation when attempting to cover the tumor with a radiation field, to avoid a "miss". it is thought that using fiducial markers called visicoils placed in or adjacent to the tumor's top and bottom extent at the time of eus, will lead to better definition of the tumor in the planning process and hence, improvement in local tumor control, and reduction in radiotherapy dose to normal tissue.


Eligibility criteria:
inclusion criteria: * esophageal adenocarcinoma or squamous carcinoma, or undifferentiated carcinoma. * no previous radiotherapy or chemotherapy. * fit for radical treatment of their cancer with reasonable lung function, fev1 \>40%, and eus planned. * ecog performance status 0-1: 0 - fully active, able to carry on all predisease performance without restriction 1 - restricted in physically strenuous activity exclusion criteria: * pregnancy or breast feeding. * allergy to ciprofloxacin antibiotics

Keywords: neoplasm staging radiotherapy fiducial markers
incidence of venous thromboembolism and cardiovascular events in breast cancer patients undergoing cyclin-dependent kinase 4/6 inhibitors: the breast cancer associated vascular events during cyclin-dependent kinase 4/6 inhibitors therapy (brave-cyclin) study

Conditions: Breast Cancer

Summary: "incidence of venous thromboembolism and cardiovascular events in patients with breast cancer treated with cyclin-dependent kinase inhibitors 4/6, the brave-cyclin study" is national, single-center, observational, prospective cohort study, conducted at fondazione policlinico universitario a. gemelli irccs. according to recent evidence, patients with advanced or metastatic breast cancer receiving cyclin-dependent kinase (cdk) 4/6 inhibitors - ribociclib, palbociclib, and abemaciclib - may have an increased risk of arterial or venous thrombosis. currently, there are no validated tools to stratify breast cancer patients receiving cdk 4/6 inhibitors according to their thromboembolic or cardiovascular risk. the prospective brave-cyclin study aims to evaluate the incidence of venous thromboembolism, major cardiovascular events, and major adverse peripheral vascular events in breast cancer patients receiving cdk 4/6 inhibitors. the objective is to identify the main determinants of thromboembolic and cardiovascular risk, thus improving risk stratification and management strategies.


Eligibility criteria:
inclusion criteria: * female sex; * diagnosis of advanced or metastatic breast cancer. * indication for therapy with cyclin-dependent kinase 4/6 inhibitor, as clinical practice; * age of 18 years or older; * signing informed consent. exclusion criteria: • pregnant or breastfeeding women.

Keywords: venous thromboembolism breast cancer cyclin-dependent kinase 4/6 inhibitors cdk 4/6 inhibitors cardiovascular disease palbociclib ribociclib abemaciclib
an epidemiological cohort study of acute coronary syndromes in the greek population. the phaethon study

Conditions: Coronary Artery Disease

Summary: a nationwide registry of patients with acute coronary disease to evaluate epidemiological patient characteristics, medical management, implementation of invasive strategy, patient outcome and impact on quality of life in greece.

a nationwide registry of patients with acute coronary disease to evaluate epidemiological patient characteristics, medical management, implementation of invasive strategy, patient outcome and impact on quality of life in greece.

Eligibility criteria:
inclusion criteria: * informed consent * \> 25 years * admission in hospital within 24 hours from beginning of symptoms of transfer from antother hospital within 24 hours from beginning of symptoms. * acute coronary syndrom exclusion criteria: -

Keywords: cad stemi non stemi unstable angina greece
a clinical trial of csl's 2009 h1n1 influenza vaccine (csl425) in healthy children

Conditions: Influenza Caused by the Novel Influenza A (H1N1) Virus

Summary: the purpose of this study is to determine whether csl425 is a safe and effective vaccine for eliciting an immune response to h1n1 influenza in healthy children.


Eligibility criteria:
inclusion criteria: * male or female aged \>= 6 months to \< 9 years at the time of the first study vaccination. * for children \< 3 years of age at the time of first vaccination, born at or after 36 weeks of gestation. exclusion criteria: * known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the study vaccine.
comparison study using apap with and without sensawake in patients with osa and ptsd

Conditions: Obstructive Sleep Apnea (OSA); Post-Traumatic Stress Disorder (PTSD)

Summary: the purpose of this research is to examine the application of autocpap with and without sensawake in subjects with osa and post-traumatic stress disorder (ptsd), and evaluate whether patients achieve better sleep quality and compliance with sensawake, compared to the same treatment without sensawake.

conceptually, awareness of pressure occurs only during wakefulness. thus reducing the pressure during wakefulness may improve therapy comfort and potentially adherence without compromising therapy efficacy. sensawake™ is a unique pressure relief technology developed by fisher \& paykel healthcare which detects irregularity in the flow signal indicative of the transition from sleep to wake. when the transition from sleep to wake is detected the device promptly reduces the pressure to help facilitate a return to sleep. it is hypothesised that autocpap with sensawake will improve patient comfort and compliance in the ptsd and osa patients who are naïve to cpap therapy. the investigators will not be blinded to the study. the participants will be blinded to the study.

Eligibility criteria:
inclusion criteria: male and female subjects \> 18 years diagnosed with osa by a practicing sleep physician, within the last six months diagnosed with post-traumatic stress disorder as diagnosed by a behavioral health professional, and quantified by mcchord ptsd checklist all races and ethnicities will be included naïve to cpap therapy (has not used cpap within the last 5 years) exclusion criteria: \< 18 years of age if mental status is questionable, the patient will be excluded at the discretion of the consenting provider unable/unwilling to follow the directions necessary for cpap use patients contraindicated for cpap/autocpap, at the discretion of the consenting provider
norepinephrine for spinal-induced hypotension

Conditions: Spinal Anesthesia

Summary: norepinephrine (ne) infusion is used prophylactically to counteract the vasodilator effect of spinal anesthesia. prophylactic use of ne infusion is expected to decrease bouts of hypotension, vomiting and increase patient satisfaction


Eligibility criteria:
inclusion criteria: * all patients scheduled for elective surgery under spinal anesthesia exclusion criteria: * ischemic heart disease uncontrolled hypertension
pilot of lifestyle and asthma intervention

Conditions: Asthma

Summary: this is to pilot test a weight loss intervention in obese patients with poorly controlled asthma. obesity is a risk factor for the development of asthma (approximately 250,000 cases per year of asthma in the u.s. are related to obesity). investigators' ultimate purpose is to test the hypothesis that weight loss through an intensive life style intervention will improve asthma control. but investigators first need to establish whether the weight loss intervention is effective in patients with asthma. objectives 1. the primary objective of this study is to determine the effectiveness of an internet-based weight loss intervention in producing weight loss in obese patients with poorly controlled asthma. 2. the ultimate purpose is to implement a multi-center weight loss intervention trial for obese patients with poorly controlled asthma.

this will be a pilot study of a weight loss intervention at two centers, the university of arizona and the university of vermont. the primary outcome of interest will be the percent of participants achieving a 5% weight loss, which is the amount of weight loss that prior studies suggest is required to improve asthma control. this will be a single arm-phase ii futility trial; the "futility" to be assessed is the ability to produce weight loss. such designs are widely used in efficiently informing decisions to proceed to phase iii clinical trials. this trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss). this is a 6-month study of 40 participants (20 at each site). all participants will be assigned to the weight loss intervention, which is described in detail below

Eligibility criteria:
inclusion criteria: * physician diagnosis of asthma on regular prescribed controller therapy for at least 3 months * age: ≥18 years of age * obese: bmi \> 30 kg/m2 * poorly controlled asthma * asthma control test score \< 19,19,20 or * use of rescue inhaler, on average, \> 2 uses/week for preceding month, or * nocturnal asthma awakening, on average,1 or more times / week in preceding month, or * emergency department (ed)/hospital visit or prednisone course for asthma in past six months * ability and willingness to provide informed consent * ability to access internet weight loss program for trial period * completion of asthma diary cards and weight loss diary cards for same 3 consecutive days at visit 2 exclusion criteria: * prior history of bariatric surgery * any condition that puts the participant at risk from participation in a weight loss study or a condition that precludes participation in regular exercise as judged by the site physician. * pregnancy (by patient self-report) * participation in another weight loss intervention within the last month * weight loss of ≥ 10 pounds in the last 6 months by self-report

Keywords: obesity asthma weight loss
custom guides for total knee arthroplasty (tka)

Conditions: Knee Osteoarthritis

Summary: the goal of the study is to know if the reconstruction of the lower limb mechanical axis and the patient knee function is improved after total knee arthroplasty (tka) using patient specific instruments.


Eligibility criteria:
inclusion criteria: * patients scheduled for a tka * informed signed consent

Keywords: knee osteoarthritis
whole-body cryotherapy (wbc) as an adjunct treatment on pain in fibromyalgia persons: short time effect.

Conditions: Fibromyalgia

Summary: our aim was to determine whether whole body cryotherapy (wbc) can result in improved pain status, perceived health, and quality of life in patients with fibromyalgia. it is hypothesized that this positive effect can be achieved through increased functional mobility and decreased pain intensity resulting from cold-induced modulation of the inflammation-immune axis.

24 patients with fibromyalgia were randomized into 2 groups (n=11 in the wbc group, n=13 in the control group). in the wbc group, 10 sessions of wbc were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days. patients in the control group did not change anything in their everyday activities. several self-reported variables relating to perceived health were measured repeatedly (pain intensity, functional mobility, and quality of life).

Eligibility criteria:
inclusion criteria: fibromyalgia diagnosis exclusion criteria: cardiorespiratory disorder current pregnancy cold intolerance embolic diseases

Keywords: whole body cryotherapy fibromyalgia chronic pain quality of life perceived health
intraocular lens-shell technique in phacoemulsification

Conditions: Cataract; Pseudoaphakia

Summary: in this study, the investigators introduce a surgical procedure called "iol-shell technique" in the purpose of reduce complications of surgeries for dense cataract, and report a prospective randomized controlled study aiming at assessing efficacy and safety of the iol-shell technique, which showed that the new procedure offered a safer way for hard cataract surgery over the conventional phacoemulsification procedure without compromise in efficacy.

a prospective, randomized controlled study of 80 eyes with dense nucleus were enrolled. patients were assigned to two groups: group i: iol was traditionally implanted after all nuclear fragments were completely removed, while in group ii, iol was innovatively implanted in the bag before last residual nuclear fragment was removed. this novel adjusted surgical procedure, featured by using iol as a protective barrier (named "iol-shell technique"), not just as a refractive alternative, was conceptual different from the traditional step-by-step procedure. clinical examinations including uncorrected visual acuity, central corneal thickness (cct), temporal clear corneal thickness and the corneal endothelial cell density were carried out.

Eligibility criteria:
inclusion criteria: * aged 50 years or above * dense cataract cases were defined as eyes in which the nuclear color was graded iv or v according to the lens opacities classification system iii (locs iii). special attention was paid in selecting cases without apparent posterior cortical layer. * no central corneal opacification * pupil diameter \>= 7 mm after full pharmacological dilation in preoperative assessment * a preoperative central endothelial cell count of \>= 1500 cells/mm2. exclusion criteria: * participants with previous intraocular surgery * abnormal lens zonules * glaucoma * high myopia (\>-6.0 diopters) * pseudoexfoliation * uveitis * diabetes mellitus * those who were not able to come for follow-up visits.

Keywords: dense cataract phacoemulsification lens-shell technique intraocular lens
clinical trial on ganoderma spore lipids combined with chemo in patients with g.i. cancers

Conditions: Gastrointestinal Neoplasms

Summary: a phase iii double-blind randomized clinical trial on the effects of ganoderma spore lipids to the immunological response in patients with g.i. cancers. the trial is randomized, double-blind. cancer patients are diagnosed based on pathology or cell biology. patients are randomized into 2 groups: both groups receive chemotherapy. either group receives ganoderma spore lipids or placebo capsules 600mg three times a day (tid) in addition to the chemotherapy. clinical evaluation includes chemotherapy drug toxicities, life quality improvement. blood biochemistry tests mainly include malondialdehyde (mda), superoxide dismutase (sod), glutathione peroxidase (gsh-px), adrenaline, nor-adrenaline, tumor necrosis factor (tnf)-α, interleukin (il)-1b, interleukin (il)-6, cell flow cytometry on th1, th2, th17, treg cytokines, as well as serum cortisol, estradiol (female), progesterone (female), testosterone (male), etc.


Eligibility criteria:
inclusion criteria: * age: 18-80, male and female. * diagnosis: imaging, cell and pathology report. * eastern cooperative oncology group (ecog) o-2, life expectancy more than 3 months. * chemotherapy is not contraindicated. * no apparent surgical trauma during the previous 2 weeks. * past treatment: * biological treatment: at least 4 weeks after previous treatment with immunotherapy or other biological; chemotherapy, at least 6 months after last treatment with chemotherapy and or target therapy. * surgery: had not received transplantation surgery, at least 2 weeks after last major surgery. exclusion criteria: * a purulent and chronic infection of wound healing delayed. * diseases of the blood system. * abnormal blood coagulation function. * severe brain disease or primary brain tumors without control, and mentally ill person. * patients with brain metastases. * pregnant or lactating women. * patients (male/female) with fertility, but the patients themselves or their spouses do not take effective contraception. * allergic constitution. * in addition, patients taking part in other clinical trials, being treated with other biotherapy or immunotherapy and researchers consider not suitable for clinical subjects for other reasons will be excluded.
cortical excitability in patients with severe brain injury

Conditions: Severe Traumatic Brain Injury; Subarachnoid Hemorrhage; Anoxic Brain Injury

Summary: the aim of the study is to evaluate the cortical excitability in the severe brain injured patients. we hypothesize that: 1. there is a continuous decrease in intracortical inhibition from healthy subjects to awake patients with severe brain injury, and to patients with impaired consciousness. 2. decreased intracortical inhibition correlate with the degree of impairment assessed with the clinical scores in patients with severe brain injury.

design: prospective controlled non-randomized study. materials and methods: 30 patients with severe brain injury and 15 healthy volunteers will be included in this study. the study design is illustrated below: 1. clinical assessment (rancho los amigos scale, functional independence measure, early functional abilities). 2. somatosensory evoked potentials. 3. transcranial magnetic stimulation: single and paired stimulation protocols. statistical evaluation: all collected data will be tested with reference to normal distribution. if the data is not distributed normally, then we will use either a logarithmic transformation before we use parametric statistics, or we will use non-parametric statistics for further calculations.further analysis of the data will be done with the help of variance analysis with an inter-individually factor as a group (awake patients vs patients with disorders of consciousness vs control persons) and intra-individually factors as 1) interstimulus intervals for transcranial magnetic stimulation and clinical scores (rlas vs fim vs efa). significance level is set to 0.05 for all effect parameters.

Eligibility criteria:
inclusion criteria: 1. severe brain injury (glasgow coma scale score (gcs) less than 8 on admission to the acute hospital); 2. stable vital functions; 3. age over 18 years old; 4. informed content from patient/relatives/legal guardian. exclusion criteria: 1. other neurological diseases than brain injury; 2. pregnancy; 3. tms contraindications (epilepsy, metallic implantants: pacemaker or medicine pump, ferromagnetic or electronically operated stapedial implants, haemostatic clips, metallic splinters in the orbit).

Keywords: severe brain injury excitability transcranial magnetic stimulation
cardiac remodeling and prognosis in secondar tricuspid regurgitation

Conditions: Remodeling, Cardiac; Tricuspid Regurgitation

Summary: the aim of this study is to improve the definition of the two main types of secondary tricuspid regurgitation.


Eligibility criteria:
inclusion criteria: * any patients ≥ 18 years old, with moderate to severe tricuspid regurgitation (≥ 2/4), agreeing to participate ; * the patients included can be ambulatory patients or stabilized hospitalised patients (meaning patient clinicaly stable, not decompensated, and whose normovolemia has been checked). * non opposition of the patient exclusion criteria: * patient whose accoustic window is judged by the operator as incompatible with a precise evaluation of the tricuspid regurgitation or anatomy of the right cavity ; * tr \< grade 2 ; * tr secondary to primary pulmonary hypertension or congenital cardiopathy ; * primary tricuspid regurgitation (due to rheumatic heart disease, medication - included benfluorex, due to endocarditis, valvular prolapse, carcinoid syndrom or a cardiac stimulation lead ...) ; * significant left heart valvulopathy (mitral regurgitation \> grade 2, aortic insufficiency \> grade 2, mitral stenosis \< 2 cm², aortic stenosis \< 1.5 cm²). a valvulopathy sucessfully operated isn't considered as an exclusion criteria; * cardiopathy with significative systolic dysfunction (fe\< 40%) ; * patients whose life expectantcy is less than 1 year due to a pathology independent of the tr (neoplasic process for example) ; * patient under judicial protection.
doctor-patient communication about colorectal cancer screening

Conditions: Colorectal Cancer Screening

Summary: the purpose of this study is to learn more about doctor-patient communication about colon cancer screening. this study will also look to see if there are differences in those who get colon cancer screening based on the discussion the doctor had with the patient.


Eligibility criteria:
inclusion criteria: physicians * attending physicians or third year residents specializing in internal medicine or family medicine, as per the medical director from the clinic. * clinic is based at a nyc ring-affiliated practice. * english speaking; due to limited resources, we cannot have each audio recorded consultation translated therefore, the consultation needs to be in english. patients * ages 50-75 years old, per the united states preventive services task force recommendations for screening. this will be determined by a pre-screening of medical records by the rsa. * due for colorectal cancer screening at the time of the visit, ascertained through patient self-report (e.g., no colonoscopy within the past 10 years, no flexible sigmoidoscopy or barium enema within the past five years, and no fobt within the past year). * coming for either an annual physical exam or chronic care follow up visit, per patient self-report. * planning to consult with the physician in english, per patient self-report. due to limited resources, we cannot have each audio recorded consultation translated therefore, the consultation needs to be in english. exclusion criteria: * history of colorectal cancer, per patient self-report or per emr.. * history of polyps being removed, per patient self-report. * colonoscopy scheduled in emr at time of screening.

Keywords: doctor-patient communication questionnaire survey 12-017